| 1.22 0.02 (1.67%) | 09-11 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 1.49 | 1-year : | 1.74 |
| Resists | First : | 1.27 | Second : | 1.49 |
| Pivot price | 1.21 |
|||
| Supports | First : | 1.16 | Second : | 1.1 |
| MAs | MA(5) : | 1.2  |
MA(20) : | 1.21 |
| MA(100) : | 1.18 |
MA(250) : | 1.37 |
|
| MACD | MACD : | 0 |
Signal : | 0 |
| %K %D | K(14,3) : | 38.4 |
D(3) : | 36.5 |
| RSI | RSI(14): 54.1 |
|||
| 52-week | High : | 3.45 | Low : | 1 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ BNGO ] has closed below upper band by 43.9%. Bollinger Bands are 33% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 1.24 - 1.25 | 1.25 - 1.25 |
| Low: | 1.19 - 1.19 | 1.19 - 1.2 |
| Close: | 1.21 - 1.22 | 1.22 - 1.23 |
Bionano Genomics, Inc. focuses on providing advanced solutions for analyzing genomes. The company's flagship offering is Saphyr, a complete system that processes samples to results, enabling the analysis of structural variations in the genome using optical genome mapping. This technology is vital for deciphering genetic variations and their functional roles. The Saphyr platform includes the Saphyr instrument, a device capable of imaging single molecules; the Saphyr Chip, a disposable component equipped with nanochannel arrays for DNA linearization; and Bionano Prep Kits and DNA labeling kits, which provide essential reagents and protocols for extracting and tagging ultra-high molecular weight DNA. Furthermore, Bionano Genomics supplies Saphyr and Bionano compute servers to support its analytical operations. It also offers NxClinical, a single software system designed for the analysis and interpretation of genomic variants identified through microarray and next-generation sequencing data, serving both cytogenetics and molecular genetics applications. In addition to its product line, Bionano Genomics delivers a variety of specialized testing and laboratory services. These include: FirstStepDx PLUS: A chromosomal microarray service used to identify underlying genetic causes in individuals with autism spectrum disorder, developmental delay, and intellectual disability. Fragile X syndrome (FXS) testing services: Comprehensive diagnostic testing for FXS. NextStepDx PLUS: An exome sequencing test aimed at detecting genetic variants associated with childhood developmental disorders. EpiPanelDx PLUS: A genetic testing panel for patients experiencing seizures, infantile spasms, encephalopathy, or febrile seizures. PGx test: A pharmacogenomics test that identifies over 60 alleles across 11 genes relevant to drug response. Bionano Genomics was founded in 2003 and operates from its corporate headquarters in San Diego, California.
Wed, 09 Sep 2026
Bionano Genomics (BNGO) interim CEO adds 4,000 shares in IRA - Stock Titan
Fri, 21 Aug 2026
Bionano Genomics (NASDAQ: BNGO) interim CEO buys 4,000 shares - Stock Titan
Mon, 17 Aug 2026
Bionano Genomics Number of Employees 2026 | Employee Count & Headcount Data - Revelio Labs
Tue, 11 Aug 2026
Bionano Genomics, Inc. 2026 Q2 - Results - Earnings Call Presentation (NASDAQ:BNGO) 2026-08-11 - Seeking Alpha
Fri, 07 Aug 2026
Earnings To Watch: Bionano Genomics Inc (BNGO) Q2 2026 -- GF Value Sees 27% Upside - Yahoo Finance
Wed, 05 Aug 2026
Bionano Genomics (NASDAQ: BNGO) awards CSO 54,000 options vesting from 2027 - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Instruments & Supplies
|
|
| Shares Out | 12 (M) |
| Shares Float | 11 (M) |
| Held by Insiders | 7.2 (%) |
| Held by Institutions | 8.4 (%) |
| Shares Short | 1,150 (K) |
| Shares Short P.Month | 1,090 (K) |
| EPS | -3.01 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 2.68 |
| Profit Margin | -106.6 % |
| Operating Margin | -88.4 % |
| Return on Assets (ttm) | -32.6 % |
| Return on Equity (ttm) | -83.6 % |
| Qtrly Rev. Growth | 21.3 % |
| Gross Profit (p.s.) | 1.21 |
| Sales Per Share | 2.56 |
| EBITDA (p.s.) | -1.95 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -20 (M) |
| Levered Free Cash Flow | 2 (M) |
| PE Ratio | -0.41 |
| PEG Ratio | 0 |
| Price to Book value | 0.45 |
| Price to Sales | 0.47 |
| Price to Cash Flow | -0.71 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|